Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Clin Cancer Res. 2011 Feb 15;17(7):1867–1874. doi: 10.1158/1078-0432.CCR-10-2021

Table 1.

Means and frequencies of participants’ characteristics by androgen receptor status (N=1467), Nurses’ Health Study (1976–1997)

Characteristic AR− AR+
N (%) 313 (21.3) 1154 (78.7)
Age at diagnosis, mean (N), yr 59.0 (313) 60.8 (1154)
BMI at diagnosis, mean (N*), kg/m2 26.6 (280) 26.0 (1041)
Smoking, N* (%)
 Never 138 (44.2) 442 (38.5)
 Past 125 (40.1) 482 (42.1)
 Current 49 (15.7) 222 (19.4)
ER status, N (%)
 Positive 140 (44.7) 1024 (88.7)
 Negative 173 (55.3) 130 (11.3)
PR status, N* (%)
 Positive 114 (36.7) 830 (72.2)
 Negative 197 (63.3) 319 (27.8)
HER2 status, N* (%)
 Positive 46 (15.0) 81 (7.1)
 Negative 260 (85.0) 1059 (92.9)
Nodal involvement, N (%)
 None 212 (67.7) 883 (76.5)
 1 – 3 78 (24.9) 220 (19.1)
 4 – 9 16 (5.1) 28 (2.4)
 ≥ 10 7 (2.3) 23 (2.0)
Tumor size (cm), N (%)
 ≤ 2 188 (60.1) 814 (70.5)
 > 2 125 (39.9) 340 (29.5)
Histological grade, N (%)
 I (low) 22 (7.0) 302 (26.2)
 II (intermediate) 127 (40.6) 692 (60.0)
 III (high) 164 (52.4) 160 (13.8)
Stage, N (%)
 I 154 (49.2) 682 (59.1)
 II 126 (40.3) 394 (34.1)
 III 33 (10.5) 78 (6.8)
Chemotherapy, N* (%)
 Yes 141 (55.7) 258 (27.4)
 No 112 (44.3) 682 (72.6)
Hormone treatment, N* (%)
 Yes 145 (58.2) 672 (71.3)
 No 104 (41.8) 270 (28.7)
Radiation treatment, N* (%)
 Yes 114 (45.4) 393 (41.6)
 No 137 (54.6) 551 (58.4)
*

N doesn’t add to total because of missing information.

Stage I=tumor size<=2cm and no nodal involvement;

II=tumor size<=2cm & 1–3 nodes or 2–4cm & 0–3 nodes or 4+cm & 0 nodes;

III=tumor size<=2cm & 4+ nodes or 2–4cm & 4+ nodes or >4cm & 1+ nodes.

HHS Vulnerability Disclosure